The phase III ATTLAS study showed that the ABCP regimen significantly extended PFS to 8.48 months compared with 5.62 months with chemotherapy in EGFR‐ or ALK‐mutated NSCLC, while the OS remained similar (20.63 vs. 20.27 months) [24]. Here, ALK is linked to non-small cell lung carcinoma.